Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dalcetrapib - DalCor Pharmaceuticals

Next Previous
X
Search
Drug Profile

Dalcetrapib - DalCor Pharmaceuticals

Alternative Names: JTT-705; R 1658; RG1658; RO 4607381

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Japan Tobacco
  • Developer DalCor Pharmaceuticals; Japan Tobacco; Montreal Heart Institute; Roche
  • Class Antihyperlipidaemics; Cyclohexanes; Small molecules; Thioesters
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute coronary syndromes
  • Phase II COVID 2019 infections
  • Discontinued Atherosclerosis; Coronary disorders; Hyperlipidaemia

Most Recent Events

  • 03 Oct 2023 Phase III clinical trial for Acute Coronary Syndrome in USA and Canada (PO) (NCT05918861)
  • 26 Jun 2023 DalCor Pharmaceuticals plans a phase III dal-GenE-2 trial for Acute coronary syndrome (In adults, In the elderly) in the US and Canada (PO, Tablets) (NCT05918861)
  • 21 Jul 2022 Efficacy and adverse events data from a phase III dal-GenE trial in Acute coronary syndromes released by DalCor Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top